Beranda › Leukemia Limfositik Kronis › Pennsylvania › Pittsburgh
Uji klinis Leukemia Limfositik Kronis di Pittsburgh, PA
10 studi untuk Leukemia Limfositik Kronis mencari peserta di lokasi sekitar Pittsburgh (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Menerima pesertaFase 3
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Menerima pesertaFase 3
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Menerima pesertaFase 3
- West Penn Hospital, Pittsburgh
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Menerima pesertaFase 2
- UPMC Hillman Cancer Center, Pittsburgh
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Menerima pesertaFase 2
- UPMC Hillman Cancer Center, Pittsburgh
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Menerima pesertaFase 1/2
- Research Site, Pittsburgh
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Menerima pesertaFase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Menerima pesertaFase 3
- UPMC Hillman Cancer Center, Pittsburgh
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Menerima pesertaFase 2
- UPMC Hillman Cancer Center, Pittsburgh
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Menerima pesertaFase 2
- AHN Cancer Institute - West Penn Hospital, Pittsburgh
Uji klinis Leukemia Limfositik Kronis di kota lain
- Boston, MA31 studi
- Columbus, OH28 studi
- Durham, NC27 studi
- Washington, DC22 studi
- Seattle, WA20 studi
- Rochester, MN19 studi
- New York City, NY18 studi
- Houston, TX17 studi
- Baldwin Park, CA16 studi
- Milwaukee, WI15 studi
- Chicago, IL14 studi
- Cincinnati, OH14 studi
Studi lain di Pittsburgh
- Kanker Paru Non-Sel Kecil48 studi
- Kanker (semua jenis)41 studi
- Kanker Payudara39 studi
- Kanker Kolorektal32 studi
- Kanker Metastatik31 studi
- Melanoma31 studi
- Kanker Ovarium30 studi
- Kanker Endometrium23 studi
- Kanker Paru23 studi
- Kanker Prostat23 studi
- Stroke22 studi
- Karsinoma Sel Skuamosa Kepala dan Leher22 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.